Xencor Inc. ((XNCR)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
In a recent update, Xencor Inc. announced the completion of a Phase 2 clinical study titled ‘Phase 2 Multiple-Dose, Multiple-Arm, Parallel Assignment Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapies in Selected Subjects With Metastatic Castration-Resistant Prostate Cancer.’ The study aimed to assess the safety and efficacy of vudalimab, both as a standalone treatment and in combination with other therapies, in patients with metastatic castration-resistant prostate cancer (mCRPC) who have not responded to previous treatments.
The intervention being tested is vudalimab (XmAb20717), which is used alone or in combination with chemotherapy or targeted therapies. Vudalimab is designed to enhance the immune response against cancer cells.
The study utilized a non-randomized, parallel assignment model with no masking, focusing primarily on treatment. It enrolled patients into five distinct cohorts based on specific molecular characteristics of their cancer.
The study began on October 22, 2021, and was completed with the last update submitted on July 16, 2025. These dates are crucial as they mark the progression and completion of the study, providing a timeline for data collection and analysis.
This update could influence Xencor Inc.’s stock performance positively, as successful results may enhance investor confidence and position the company favorably against competitors in the oncology sector. The study’s completion without reported results may also prompt cautious optimism among investors.
The study is now completed, with further details available on the ClinicalTrials portal.